In 4Q15, Vexim achieved the key milestone of 25,000 SpineJack® units sold since the market launch in 2011.
This follows a 3Q15 quarterly sales record of €3.6MM (~US $3.9MM), +44% from 3Q14.
SpineJack is designed to support anatomical restoration of vertebral compression fractures (VCFs) caused by trauma. The range of sizes, from 4.2mm to 5.8mm, may be used to address 95% of all VCFs.
In 2Q15, the company announced 1-year results from a pilot feasibility study comparing VCF treatment with SpineJack to Medtronic's balloon. Results demonstrated that SpineJack was highly effective, resulting in greater/sustainable restoration of vertebral height, faster pain relief and shorter OR time.